DAY TWO - Stream B: Stem Cells for Drug Discovery

last modified: 22 May '12

Please enable javascript to see more information on speakers

2.05pm

Chairman’s opening remarks

Anand Gadre

Anand Gadre graduated with his BS from the University of Mumbai (India) in 1994. He received the MS Degree at the Institute of Science in 1997. During his Master’s degree, his research was involved in characterizing the structural, electrical and...

more..

› Anand Gadre, Director Stem Cell Instrumentation Foundry, University of California

ADVANCES IN STEM CELL DIFFERENTIATION

2.10pm

Stem cell-based projects in a global pharmaceutical organization

Arnaud Lacoste

Arnaud Lacoste is a Project Team Leader at Novartis where he pioneered the use of reprogramming technologies and patient-derived pluripotent stem cells for drug discovery and development. Dr Lacoste’s group is in charge of large-scale production and ...

more..

What are the scientific solutions towards the routine use of stem cells in drug discovery?
What are the management challenges associated with the development of stem cell platforms?
How best to define the cell culture conditions, manipulate cell fate to uncover the treatment of disorders?
How can we direct and redirect cell fate accurately in vitro?

› Arnaud Lacoste, Project Team Leader Stem Cells & Regenerative Medicine, Novartis

2.35pm

Technological advancements to make stem cells standard practice in drug discovery

Tristan McKay

Tristan McKay obtained his Bachelors degree from University of Essex, a Master’s degree from Imperial College and graduated with a Ph.D from Imperial College in 2000 having developed new gene therapy approaches to the hepatobiliary manifestations of ...

more..

Genetic reporters of differentiation & disease in cells
Controlling cellular differentiation and disease induction
Meeting the need to match the substrate with the relevant cell fate and ensure differentiation is repeatable
Developing unique methods to differentiate ES/iPS cells as well as whole body systems
What to do with a successfully differentiated stem cell: use for toxicity, use for efficacy and use to understand disease pathways

› Tristan McKay, Senior Lecturer, Stem Cell Biology, Queen Mary University of London

IDENTIFYING AND VALIDATING TOXICOLOGY OF DRUGS

2.50pm

Assays to predict cardiac safety early in development of all new drugs

Stefan Braam

Stefan Braam is a research scientist at the Leiden University Medical Center, furthermore he is the scientific founder and Chief Scientific Officer of the LUMC spin-off company Pluriomics BV. He has over 7 years of pluripotent stem cell experience...

more..

Introduction - current model systems in drug discovery & development
Potential of pluripotent stem cell models, their expected advantages and the remaining challenges
Cardiac safety pharmacology assay development & validation
What have been the results of collaborations with big pharma?

› Stefan Braam, CSO, Pluriomic

3.15pm

Carrying out essential toxicity testing with improved predictive tools

Frank Bonner

Frank Bonner is Chief Executive of Stem Cells for Safer Medicines, a Public-Private partnership which is focussed upon developing stem cell assays for predictive toxicology. Frank has over 25 years of experience of toxicology and non-clinical drug...

more..

Moving forward with stem cells for drug screening and toxicity profiling
Utility and value to derive more predictive testing platforms
How well do stem cell-based models model real life metabolic activity?
SC4SM Predictive Toxicology Consortium; update and next steps

› Frank Bonner, CEO, Stem Cells for Safer Medicine

3.40pm

Afternoon refreshments

4.10pm

Using stem cell technology for drug target discovery and toxicity testing

Dr David Hay

Dr David Hay is a Group Leader at the University of Edinburgh’s MRC Centre for Regenerative Medicine. David carried out his PhD at the University of St Andrews. Following this he relocated to the Roslin Institute and subsequently to the Centre for...

more..

Stem cells offer an unlimited source of hepaotcytes for human drug screening
Stem cell derived hepatocytes exhibit phenotypic instability in culture
We have identified a novel support which stabilises hepatocellular phenotype
We have validated our model working with Pharma

› Dr David Hay, Principal Investigator, RCUK Fellow, MRC Centre for Regenerative Medicine

4.35pm

Using Stem Cell-derived Cardiomyocytes in Drug Screening and Predictive Cardiotoxicity

Dr Heribert Bohlen

Dr. Heribert Bohlen MD, PhD Chief Executive Officer is co-founder and CEO of Axiogenesis for the last 10 years where he developed stem cell derived cells, tissue models and disease models. Axiogenesis’ core business is in the area of pharmaceutical...

more..

· Stem cell derived cardiomyocyte cell model prevents late drug failure by providing a physiological test system early on in development

· All mechanisms of action are shown to work in a physiological manner

· One cardiomyocyte can be used in all assays

· The potential for tissue specific answers long before in vivo studies

› Dr Heribert Bohlen, CEO, Axiogenesis

USING STEM CELLS FOR FUNCTIONAL ANALYSIS AND TARGET DISCOVERY

4.50pm

Platforms for predictive toxicology and safety screening with cardiomyocytes

Amy Pointon

I obtained my PhD entitled ‘Role of transcriptional and translational gene regulation in the mechanism of doxorubicin cardiotoxicity’ in 2009 from the MRC Toxicology Unit based at the University of Leicester. Following this I obtained a post...

more..

Recent advances in human embryonic and induced pluripotent stem cell technology represent a new opportunity for assessing cardiac drug safety.
Development of these systems to high through-put screening will be discussed.
The utility to provide mechanistic insight into toxicity and future advances